17 results about "Carbohydrate chains" patented technology

The invention discloses an N-sugar chain marker combination for predicting the curative effect state of IgA and IgG type MM and a prediction scoring system and application of the N-sugar chain marker combination. The N-sugar chain marker combination is composed of the following 11 N-sugar chains: NGA2, NGA2F, NG1A2F-1, NG1A2F-2, NA2, NA2F, NA2FB, NA3, NA3Fb, NA4 and NA4Fb. The method has the advantages that (1) the relevance between the N-carbohydrate chain and the curative effect in the blood of the IgA and IgG type MM patients in different curative effect states is found for the first time, and the N-carbohydrate chain can be used as an index for predicting the curative effect states of the IgA and IgG type MM patients for the first time; and (2) the N-carbohydrate chain curative effect prediction scoring system provided by the invention is used for predicting the curative effect states of IgA and IgG type MM patients, and a new technical means is provided for predicting the curative effects of the IgA and IgG type MM patients.

The invention belongs to the technical field of biological detection, and particularly relates to a method for analyzing and detecting IgG N-glycan in dried blood spots. The dried blood spot sample is adopted to replace a traditional serum sample, so that the technical problem of IgG N-carbohydrate chain degradation under the normal-temperature storage condition of the serum sample is effectively solved, and the stability of the sample and the reliability of a detection result are remarkably improved. The dried blood spot sample collecting method is simple and convenient, vein blood sampling is not needed, the method is suitable for large-scale screening and application of special crowds, and the clinical application range of IgG N-glycan analysis is widened. Besides, the dried blood spot sample can be stored for a long time at room temperature, the transportation and storage cost is reduced, meanwhile, analysis can be completed only through a trace amount of blood, the method is suitable for repeated sampling and long-term monitoring, and a technical support is provided for research and application of IgG glycosylation as a biomarker.

The invention provides a preparation method of an antibody conjugate containing an sLeX tetrasaccharide structure, which comprises the following steps: S1, sequentially adding Endo S2 enzyme and alpha-L-fucosidase into a target antibody, and respectively analyzing glycosylation to avoid modification site conflict or carbohydrate chain structure interference; s2, adding the accurately represented antibody in the S1, B4GalT1 and UDP-Gal into a Tris-HCl system containing Mn < 2 + >, and incubating to obtain a reaction solution I; s3, the reaction liquid I, ST3Gal3, CMP-Neu5Ac and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is carried out; adding CMP-N-acyl neuraminic acid phosphodiesterase for reaction, and purifying Protein A to obtain a purified antibody I; s4, the purified antibody I, alpha1, 3 FucT-2HR, GDP-Fuc and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is performed; and purifying Protein A to obtain a target product. According to the modified antibody obtained by the invention, while the targeting property is improved, the binding affinity of the antibody and a tumor cell surface antigen can be enhanced, so that the immune blocking activity of the antibody is further enhanced, and dual improvement of the targeting property and the activity is realized.

The invention discloses a method for prolonging the half-life period of polypeptide by introducing composite N-glycosylation modification, which comprises the following steps: expressing trypanosoma buchneri-derived oligosaccharyl transferase TbSTT3A in insect cells; the method comprises the following steps: synthesizing a mutant GLP-1M containing asparagine by using GLP-1; oligosaccharide in the humanized compound fatty alcohol oligosaccharide is transferred to GLP-1M by utilizing the catalysis of oligosaccharyl transferase TbSTT3A, so that the humanized compound N-glycopeptide with prolonged half-life period is obtained. According to the invention, a conventional complex in-vivo human N-carbohydrate chain biosynthesis pathway is broken, fatty alcohol oligosaccharide containing a human compound N-carbohydrate chain is synthesized in vitro, oligosaccharyl transferase TbSTT3A with high substrate adaptability is used for catalysis, and the compound N-carbohydrate chain is transferred from the fatty alcohol oligosaccharide to GLP-1M polypeptide, so that the stability of GLP-1M is remarkably enhanced, and the human N-carbohydrate chain-containing fatty alcohol oligosaccharide-GLP-1M can be used for preparing the GLP-1M-GLP-1M-GLP-1M-GLP-1M-GLP-1M-GLP-1M-GLP-1M. And a new strategy for prolonging the half-life period of the GLP-1 is provided.

The invention relates to the technical field of biomedical detection and data processing, and discloses an esophageal cancer risk assessment system and method based on a serum N-glycosylation spectrum.The system obtains multi-dimensional detection data containing a collision sectional area, distinguishes N carbohydrate chain isomers by means of the data and generates original feature vectors; the method comprises the following steps: calculating a step-by-step truncation ratio of key enzyme nodes according to N sugar chain biosynthesis network topology, and constructing a dynamic enzyme effect feature vector; carrying out individualized correction on an esophageal tumor basic template by utilizing the vector, carrying out deconvolution on an original signal into a hepatogenic background and an esophageal tumor source signal through a non-negative least square method, and calculating an esophageal tumor leakage coefficient representing a tumor contribution degree; and finally, carrying out weighted fusion on the leakage coefficient and the risk-associated enzyme feature to judge the risk level. By analyzing enzymatic kinetics and separating trace tumor signals, isomer overlapping and background interference are overcome, and evaluation sensitivity is improved.

The invention discloses an SSR4 gene edited CHO (Chinese Hamster Ovary) cell line as well as a preparation method and application thereof. The preservation number of the cell line is CCTCC (China Center For Type Culture Collection) NO: C2025176. An endogenous strong promoter (CMV) and a resistance selection marker are carried by a lentiviral vector, stable high expression (greater than 5 times) of SSR4 in CHO-S cells is realized, the cell growth rate is not influenced, the processing efficiency of glycoprotein in endoplasmic reticulum is further optimized, the proportion of HM glycotypes is remarkably reduced, excessive intervention of a traditional method on end modification of a carbohydrate chain is avoided, and the method has a good application prospect. Finally, accurate control of antibody drug glycosylation modification and stability improvement among batches are achieved, scientific innovation and industrial practicability are achieved, and a technical foundation is laid for high-quality production of next-generation antibody drugs.

Disclosed are compositions and formulations for removing dental calculus which comprise enzymes or other biocatalysts which cleave (i) surface-accessible nucleic acid polymers and (ii) glycoprotein carbohydrate chains at galactose residues. Optionally, one or more proteolytic enzymes are included. The compositions destroy the structural integrity of the calculus, allowing it to be readily removed without requiring special treatment by a trained dental professional. Also disclosed are methods for removing dental calculus using the disclosed compositions and formulations.

The utility model relates to the field of teaching aids, in particular to a cell membrane inlaid flowing three-dimensional dynamic model, which comprises a phospholipid bilayer model, at least one carbohydrate chain module, at least one movable membrane protein molecule module and at least one ion module, the phospholipid bilayer model comprises a phospholipid molecule upper layer model composed of a phospholipid molecule head module and a phospholipid molecule tail module, and a phospholipid molecule lower layer model composed of a phospholipid molecule head module and a phospholipid molecule tail module. Meanwhile, a penetrating type membrane protein molecule module, a semi-embedded type membrane protein molecule module, a full-embedded type membrane protein molecule module and a floating type membrane protein molecule module are further arranged on the phospholipid bilayer model. The three-dimensional model for dynamically displaying the cell membrane fluidity and the types, functions and motion modes of the membrane proteins improves the teaching effect of related knowledge of the cell membranes, and meanwhile, the model is detachable, easy to assemble and convenient to store and transport.

The invention discloses a sphingolipid ceramide N-deacylase mutant. The mutant is formed by amino acid mutation in sphingolipid ceramide N-deacylase as shown in SEQ ID NO.1, and the amino acid mutation is selected from one or more of mutation of the 232 site Tyr, mutation of the 254 site Asn, mutation of the 416 site Phe and mutation of the 592 site Leu. The invention also discloses application of the mutant in preparation of ganglioside derivative molecules by efficient enzymatic synthesis. The stability of the sphingolipid ceramide N-deacylase SCDase mutant is improved, and the pyrolysis chain temperature Tm of the mutant is improved by 5.79 DEG C compared with that of a wild type; the sphingolipid ceramide N-deacylase SCDase mutant provided by the invention enhances the enzyme preparation efficiency of ganglioside, especially for short-chain fatty acids (carbohydrate chain length lt; and 4) the synthetic activity is improved by more than two times, and the result broadens the practical application value of the SCDase enzyme.

Compositions and formulations for removing dental calculi are disclosed comprising an enzyme or other biocatalyst that cleaves (i) a surface accessible nucleic acid polymer and (ii) a glycoprotein carbohydrate chain at galactose residues. Optionally, one or more proteolytic enzymes are included. The composition disrupts the structural integrity of the stone so that it is easy to remove without the need for special treatment by a training primordial dental professional. Also disclosed are methods for removing dental calculi using the disclosed compositions and formulations.

Disclosed are compositions and formulations comprising enzymes or other biocatalyst that cleave surface-accessible DNA polymers and / or glycoprotein carbohydrate chains at galactose residues in dental calculus, and optionally further include one or more proteolytic enzymes, thereby destroying the structural integrity of the calculus, and allowing it to be readily removed without requiring special treatment by a trained dental professional. Also disclosed are methods for removing dental calculus using the disclosed compositions and formulations.

The invention discloses a magnetic hydrothermal carbon material reversely wrapped by an unmarked cell membrane as well as a preparation method and application of the magnetic hydrothermal carbon material, magnetic carbon nanospheres are prepared by a hydrothermal method, and then carboxyl groups on the surfaces of the magnetic carbon nanospheres and residual amino groups of lectin such as concanavalin A are subjected to amide condensation, so that lectinized hydrothermal magnetic carbon nanospheres are obtained. Finally, agglutination reaction can be carried out on agglutinin and carbohydrate chains on the outer surface of the cell membrane, so that the cell membrane is wrapped from inside to outside. The biomimetic material can screen drugs acting on the inner side of a cell membrane, does not need to label the cell membrane, can reduce damage to membrane protein, provides a new technical means for deeply exploring lead compounds in natural products, and promotes development of traditional Chinese medicine anti-osteoporosis drugs. According to the invention, two novel potential anti-osteoporosis components targeting the inner surface of an osteoblast cell membrane in herba epimedii are successfully found.

Provided are methods of synthesizing glycolipids. The methods combine chemical and enzymatic transformations to rapidly provide diverse natural and functionalized glycolipids in a high convergent matter. Stepwise enzymatic elongation of a carbohydrate chain of a common glycolipid precursor, compound (1), provides glycan intermediates of Formula (II), using sugar-nucleotides as glycosyl donors and glycosyltransferases as enzymes. Also provided are glycan intermediates of Formula (II) and alkene intermediates of Formula (IV) and methods of preparing same.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a metal platinum heterozygote for synergistically regulating polyamine uptake and PD-L1 glycosylation modification as well as a preparation method and application of the metal platinum heterozygote. The compound 5a takes oxaliplatin as a parent nucleus, has a cyclopropyl terminal fragment structure, shows the highest cytotoxicity and remarkable cell selectivity on non-small cell lung cancer, is good in stability, can reduce tumor progression and prolong the lifetime, and is a chemotherapy candidate drug for treating non-small cell lung cancer. The compound 5a provided by the invention has a good tumor killing effect in vitro, inhibits migration of tumor cells and induces apoptosis of the tumor cells. According to the present invention, the MAN2A1 coding the N-carbohydrate chain maturase is determined as the key immunomodulatory gene, and the compound 5a can simultaneously inhibit the polyamine uptake, mediate the modification of the N192 site high mannose type N-carbohydrate chain in PD-L1 through the MYCN / ODC / AKT / NF-[kappa] B pathway, target the non-small cell lung cancer metastasis, and rescue the immunosuppression of platinum-containing chemotherapy.

The invention discloses an N-carbohydrate chain marker for evaluating lymph node metastasis of early gastric cancer and application of the N-carbohydrate chain marker. In particular, the present invention relates to a product (e.g., a kit, a device, an operable system and / or a combination thereof) for the assessment (e.g., prediction, diagnosis and / or progression assessment) of lymph node metastasis in an early gastric cancer subject, comprising: reagents, instruments and / or systems for detecting non-fucosylated N-glycans in a sample obtained from a subject, the detection may include, for example, the determination of the level of at least one non-fucosylated N-glycan selected from the group consisting of: the detection of one, two, three, 4, 5, or all of H4N3L1, H6N3, H6N5E1, H4N7E1, H6N3E1, and H7N6L1E2. The invention further relates to application of a substance of the N-glycan level of total protein of an early gastric cancer object to preparation of a product for evaluating gastric cancer lymph node metastasis of the object, and a method for screening drugs and / or therapies.

This invention relates to glycosyltransferase and an application thereof. Specifically, provided is using glycosyltransferase GT29-32, GT29-33, GT29-34, GT29-4, GT29-5, GT29-7, GT29-9, GT29-11, GT29-13, GT29-17, GT29-18, GT29-19, GT29-20, GT29-21, GT29-22, GT29-23, GT29-24, GT29-25, GT29-36, GT29-37, GT29-42, GT29-43, GT29-45, GT29-46, PNUGT29-1, PNUGT29-2, PNUGT29-3, PNUGT29-4, PNUGT29-5, PNUGT29-6, PNUGT29-7, PNUGT29-8, PNUGT29-9, PNUGT29-14, and PNUGT29-15, and derived polypeptides thereof to catalyze the first glycosyl at position C-20, the first glycosyl at position C-6, and the first glycosyl at position C-3 of a tetracyclic triterpene compound substrate to elongate a carbohydrate chain, thereby obtaining a catalytic reaction of ginsenoside products such as ginsenoside Rg3, ginsenoside Rd, ginseno-side Rb 1, ginsenoside Rb3, saponin DMGG, saponin DMGX, gypenoside LXXV, gypenoside XVII, gypenoside XIII, gypenoside IX, notoginsenoside U, and notoginsenoside R1, notoginsenoside R2, notoginsenoside R3, 3-0-13-(D-xylopyranosyl)-13-(D-glucopyra-nosyl)-PPD, 3-0-13-(D-xylopyranosyl)-13-(D-glucopyranosyl)-CK, 20-O-Glucosylginsenoside Rf, and Ginsenoside F3. The glycosyltransferase can further be applied to construction of artificially synthesized ginsenoside, novel ginsenoside, and derivatives thereof.

The present invention, in the field of bioengineering and biotechnology, relates to a method for preparing a recombinant antibody with a unique glycan profile produced by a genome-edited CHO host cell. Specifically, according to a method of the present invention, the TALEN technology is used to edit the FUT8 gene in CHO cells that have been adapted for serum-free suspension growth. The edited CHO host cells can produce recombinant antibodies with a unique glycan profile. The unique glycan profile can be characterized by non-fucosylated N-linked oligosaccharide chains of the antibodies, extremely low N-glycosylation heterogeneity and uniform carbohydrate chains. The antibody prepared by the method of the invention exhibit significantly increased ADCC and greater stability.